Opicapone has proved effective for the treatment of end-of-dose motor fluctuations in patients with Parkinson’s disease. Here, Prof. Ray Chaudhuri (King’s College Hospital, London, UK) discusses the effect of disabling fluctuations and dyskinesias on patient quality of life, efficacy and safety of opicapone, and the best way to incorporate this treatment into practice.
Questions:
- For people with Parkinson’s disease, the emergence of disabling fluctuations and dyskinesias can severely impact quality of life; how does this affect patients, and how is it currently managed? (00:21)
- What is currently known about the efficacy and safety of opicapone in treating Parkinson’s disease? (02:13)
- What are your findings in effect on quality of life and non-motor symptoms in this analysis of opicapone? (03:10)
- How could opicapone be incorporated into practice to best support people with Parkinson’s disease and motor fluctuations? (05:03)
The abstract titled ‘OCEAN Study in Parkinson’s: Status Update of a Randomised Double-Blind Placebo-Controlled Trial of Opicapone’ (Abstract #EPO-377) was presented at the European Academy of Neurology Congress 2022, 25–28 June 2022.
Disclosures: Ray Chaudhuri has participated in advisory boards for AbbVie, UCB, GKC, Bial, Cynapsus, Lobsor, Stada, Zambon, Profile Pharma, Synovion, Roche, Therevance, Scion, Britannia, Acadia, 4D Pharma and Medtronic; received honoraria for lectures from AbbVie, Britannia, UCB, Zambon, Novartis, Boeringer Ingelheim, Bial, Kyowa Kirin, SK Pharma; investigator initiated grants from Bial, Britannia Pharmaceuticals, AbbVie, UCB, GKC; Aacdemic grants from EU Horizon 2020, Parkinson’s UK, NIHR, Parkinson’s Foundation, Wellcome Trust; Kirby Laing Foundation, MRC; royalties or licenses from Oxford (book), Cambridge publishers (book), MAPI institute (KPPS, PDSS 2); and payment for expert testimony from GMC.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of EAN 2022.
